Intensive BP Control Slows CKD Progression Only in Select Patients

Major Finding: Compared with standard BP control, intensive BP control failed to slow the progression of CKD, prevent the development of end-stage renal disease, or prevent death in most patients who had mild to moderate chronic kidney disease. Intensive BP control was beneficial only in the subgroup of patients who had proteinuria with a protein:creatinine ratio greater than 0.22 at baseline.

Data Source: AASK, a clinical trial with an initial 4-year randomized phase comparing intensive BP control with standard BP control in 1,094 black adults, as well as an observational cohort phase with a further 4-8 years of extended follow-up.

Disclosures: This study was funded by the National Institute of Diabetes and Digestive and Kidney Diseases, the Office of Research in Minority Health, and the National Institutes of Health. King Pharmaceuticals provided financial support and donated antihypertensive medications to each clinical center. Pfizer, AstraZeneca, GlaxoSmithKline, Forest Laboratories, Pharmacia, and Upjohn also donated antihypertensive drugs. None of these companies had any role in the design of the study, the accrual or analysis of data, or the preparation of the manuscript. Some of the investigators reported being in consultant and/or advisory board roles or receiving funds from numerous companies including Daiichi-Sankyo, Novartis, Amgen, King Pharmaceuticals, Abbott, Boehringer-Ingelheim, Litholink, Eli Lilly, Takeda, Merck, and Watson.